about
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell linesNew and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.Effect of Salvia miltiorrhiza root extract on brain acetylcholinesterase and butyrylcholinesterase activities, their mRNA levels and memory evaluation in rats.The significance of lumican expression in ovarian cancer drug-resistant cell lines.The MAOA, COMT, MTHFR and ESR1 gene polymorphisms are associated with the risk of depression in menopausal women.New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.The importance of polymorphic variants of collagen 1A2 gene (COL1A2) in the development of osteopenia and osteoporosis in postmenopausal women.New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.The polymorphisms of methionine synthase (MTR) and methionine synthase reductase (MTRR) genes in pathogenesis of preeclampsia.Coexistence of ACE (I/D) and PAI-1 (4G/5G) gene variants in recurrent miscarriage in Polish population.Contribution of inherited thrombophilia to recurrent miscarriage in the Polish populationCorrelation between factor VII and PAI-1 genetic variants and recurrent miscarriagePlasma purine turnover metabolites in women with normal pregnancy and pregnancy complicated with induced hypertension as compared to fetal well-being indicesThe RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis
P50
Q37349707-7E56995B-FAFC-4A9D-8A2B-8FCF19A6E8C3Q38700421-4DD8AE63-3DA6-4AE0-90A6-68746EF8C9D0Q38709065-8741A350-2532-4369-8CF7-3BF60A1CCDEDQ38951326-97B2A492-D93A-457C-9E02-3FB16E90139FQ47132524-8AD1A6A7-97CB-4A89-9229-FE5B28AA425FQ48069523-7A03751D-553B-405D-A52B-3F30EFCDD4DDQ48190854-72C278F2-96DE-450B-9213-209C6661D8FCQ49994474-F9CD3216-2FB3-4A6A-B750-DBCD92C74D9BQ52591916-59100D8F-84F6-436D-858D-B08D5AEA358FQ52838915-E7F24AC1-CFDA-4A80-A00F-4DBD6312088BQ54152116-C879FF1D-6944-4A6C-97AB-669680B4D6B4Q61838229-44B1691F-6646-42C6-890D-40035B1BD736Q61838635-8D3BA6A6-AA35-40E8-BBBE-56A8CD06F1E2Q73317628-FEF689B5-D6E5-4022-9F92-F606B38DF74EQ87673122-B81075A9-FED3-4FB2-88CF-1B2D611234D6
P50
description
Pools onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrzej Klejewski
@ast
Andrzej Klejewski
@ca
Andrzej Klejewski
@cs
Andrzej Klejewski
@en
Andrzej Klejewski
@es
Andrzej Klejewski
@gl
Andrzej Klejewski
@hr
Andrzej Klejewski
@hsb
Andrzej Klejewski
@it
Andrzej Klejewski
@nl
type
label
Andrzej Klejewski
@ast
Andrzej Klejewski
@ca
Andrzej Klejewski
@cs
Andrzej Klejewski
@en
Andrzej Klejewski
@es
Andrzej Klejewski
@gl
Andrzej Klejewski
@hr
Andrzej Klejewski
@hsb
Andrzej Klejewski
@it
Andrzej Klejewski
@nl
prefLabel
Andrzej Klejewski
@ast
Andrzej Klejewski
@ca
Andrzej Klejewski
@cs
Andrzej Klejewski
@en
Andrzej Klejewski
@es
Andrzej Klejewski
@gl
Andrzej Klejewski
@hr
Andrzej Klejewski
@hsb
Andrzej Klejewski
@it
Andrzej Klejewski
@nl
P214
P106
P1153
6603729041
P1412
P1559
Andrzej Klejewski
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-6104-3499
P735
P7859
viaf-167167478